EP3008073A1 - Thiéno[2,3-b]pyridines utilisées comme modulateurs de la résistance multiple aux médicaments - Google Patents

Thiéno[2,3-b]pyridines utilisées comme modulateurs de la résistance multiple aux médicaments

Info

Publication number
EP3008073A1
EP3008073A1 EP13750135.9A EP13750135A EP3008073A1 EP 3008073 A1 EP3008073 A1 EP 3008073A1 EP 13750135 A EP13750135 A EP 13750135A EP 3008073 A1 EP3008073 A1 EP 3008073A1
Authority
EP
European Patent Office
Prior art keywords
pyridine
amino
carboxylic acid
thieno
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13750135.9A
Other languages
German (de)
English (en)
Other versions
EP3008073B1 (fr
Inventor
Ivars Kalvins
Aivars Krauze
Signe Grinberga
Laura Krasnova
Elina Jaschenko
Ilona Domracheva
Ilze Adlere
Zigmars Andzans
Irina Shestakova
Gunars Duburs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of EP3008073A1 publication Critical patent/EP3008073A1/fr
Application granted granted Critical
Publication of EP3008073B1 publication Critical patent/EP3008073B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to novel thieno[2,3-3 ⁇ 4]pyridine derivatives and their use as multidrug resistance modulators to increase the effectiveness of chemotherapy in cancer treatment.
  • MDR Multidrug resistance
  • P-glycoprotein (the best studied target for reverting MDR), multidrug resistance-associated protein (MRPl) and the breast cancer resistance protein (BCRP) as a major MDR proteins actively transport a wide variety of structurally different substrates out of the tumor cells, thereby decreasing their intracellular concentrations.
  • MRPl multidrug resistance-associated protein
  • BCRP breast cancer resistance protein
  • Many actual chemotherapeutic agents are considered as potential P-gp, MRPl and BCRP substrates (Szakacs et al, Nat Rev Drug Discov 3: 219-34 (2006); Szakacs et al, Drug Resistance in Cancer Cells 1-20 (2009)).
  • the functional unit of an ABC transporter contains two transmembrane domains (TMDs) and two nucleotide ATP-binding domains (NBDs).
  • Transporters such as ABCG2 (BCRP) contain only one TMD and one NBD forms dimers.
  • ABC transporters have been found to be overexpressed in cancer cell lines under selective conditions. It was shown that the major mechanism of MDR in most cultured cancer cells involves P-gp, MRPl and BCRP transport proteins. ABC transporters control not only the drug release to the cell, but also the intracellular compartmentalization or division between the cytoplasm and nucleus.
  • P-gp a member of the ABCB subfamily, confers the strongest resistance to the wide variety of compounds.
  • P-gp transports vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes.
  • P-gp is normally expressed in epithelium of the liver, kidney and gastrointestinal tract at pharmacological barrier sites in stem cells and cells of immune system.
  • MRPl is a member of ABCC subfamily and confers resistance to several hydrophobic compounds that are also P-gp substrates. However, MRPl can export glutathione, glucuronate or sulphate conjugates of organic anions. MRPl is expressed in wide range of tissues, tumors and cancer cell lines.
  • BCRP is a member of ABCG subfamily. The substrate specificity of BCRP overlaps considerably with that of P-gp. BCRP is involved in the mechanism of resistance to a topoisomerase I inhibitor (topotecan) or topoisomerase II inhibitor (mitoxantrone). BCRP does not act on paclitaxel or vincristine transport, which are excreted by P-gp, and BCRP is involved in excretion of a camptothecin derivative, which is barely transported by P-gp (Kruijtzer et al, J Clin Oncol 20: 2943-50 (2002)). BCRP is expressed in many normal tissues, including liver, placenta, brain, hematopoietic stem cells and other types of stem cells.
  • MDR modulators which are non-toxic, have weak influence (or no influence) on cardiovascular system and would effectively inhibit adenosine triphosphate binding cassette transport - modulate multidrug resistance in tumor cells and rise effectiveness of chemotherapy.
  • thieno[2,3-3 ⁇ 4]pyridines are known to be biologically active substances, possessing, for example, PI3K inhibition activity, antiviral activity, osteogenesis promotion activity and modulating properties towards metabotropic glutamate receptors.
  • thieno[2,3-£]pyridines having phosphatidylinositide 3-kinases (PI3K) inhibitors activity have been disclosed in WO 2012/003262 Al .
  • Thieno[2,3-3 ⁇ 4]pyridines proposed as inhibitors of human mitogen-activated protein kinase (MEK) enzymes are disclosed in WO 2009/153554 Al, WO 2009/013462 Al, WO 2009/093008 Al, WO 2007/088345 Al .
  • Thieno[2,3-£]pyridines possess antiviral activity, and more specifically are useful for treating HIV (Human Immunodeficiency Virus) infection (WO 2010/130842 Al, WO 2009/062288 Al) or Hepatitis C (US 2006/0019976 Al).
  • Thieno[2,3-£]pyridines have been reported to be useful for promoting osteogenesis, suppresing bone resorption and/or improving bone density; for prevention or treatment of osteopathy (for example, osteoporosis, in particular postmenopausal osteoporosis, senile osteoporosis or secondary osteoporosis caused by the use of steroids or immunosuppressants), osteopenia or bone destruction associated with rheumatoid arthritis, Paget's disease of bone, bone fracture or dysostosis due to dwarfism or osteoarthritis (EP 1764367 Al).
  • osteopathy for example, osteoporosis, in particular postmenopausal osteoporosis, senile osteoporosis or secondary osteoporosis caused by the use of steroids or immunosuppressants
  • osteopenia or bone destruction associated with rheumatoid arthritis Paget's disease of bone, bone fracture or dysostosis due to dwarfism or osteoarthritis (EP
  • Thieno[2,3-3 ⁇ 4]pyridines have been claimed as potent modulators of metabotropic glutamate receptors (for mGluR5 and mGluRl receptor subtype reported in WO 2007/072090 Al and WO 2007/072091 Al, mGluR2 receptor subtype reported in WO 2006/030031 Al).
  • IKK ⁇ kinase
  • Thieno[2,3-3 ⁇ 4]pyridines have been reported as vanilloid receptor 1 (VR1 or TRPV1) antagonists in WO 2006/068618 Al .
  • Thieno[2,3-3 ⁇ 4]pyridines are active on the GABA B receptor and can be used in treating CNS disorders (WO 2006/063732 Al).
  • Thieno[2,3-£]pyridines that are selective allosteric modulators of the M 4 subtype of muscarinic receptors, useful for treatment of disorders associated with M 4 muscarinic receptors have been reported in WO 2006/047124 Al .
  • R 1 is Ci_ 4 alkyl, C 6 H 5 , 3,4,5-(OMe) 3 C 6 H 2 , NH 2 ;
  • R 2 is H, CN, COMe, COOCi_ 4 alkyl, COOC 2 H 4 OCi_ 4 alkyl;
  • R 3 is C 6 H 4 R 6 , 3,4-OCH 2 0-C 6 H 3 ; 2-furanyl;
  • R 6 is 4-Cl, 4-N0 2 , 4-N(Ci_ 4 alkyl) 2 , 3-(Ci_ 4 alkyloxy), 4-(Ci_ 4 alkyloxy),
  • R 4 is NH 2 , NHCOMe
  • R 5 is CN, COMe, COC 6 H 4 R 7 ; CO-(2-naphthyl);
  • R 7 is H, 4-F, 4-Cl, 3-OMe, 4-OMe, 2,4-(OMe) 2 , 3,4,5-(OMe) 3
  • 2-COAr, 3-NH 2 , 4-Ar, 5-COMe or 5-COOAlk and 6-Me groups are essential and together with thieno[2,3-3 ⁇ 4]pyridine scaffold determine MDR modulating activity.
  • Exchange of COAr group in position 2 for COMe, CONHAr or CN groups, acylation of amino group in position 3, removing of acetyl or ester groups in position 5 (in case of 5-H and 5-CN substituents), as well as exchange of Me group in position 6 with aryl or amino groups lead to diminution of activity.
  • R 1 Me
  • R 2 COOAlk
  • R 3 3,4,5-(OMe) 3 C 6 H 2
  • Thieno[2,3- yridines with varied MDR-blocking activity (OSI-9767, OSI-9995, OSI-9998, OSI-9999, OSI-10102, OSI-10103, OSI-10125, OSI-10205, OSI-10206, OSI- 10267, OSI- 10302) exceeding significantly reference compounds Verapamil, MK-571, Reversan and Glivec, reveal more than ten times lower Ca 2+ antagonist effect than Verapamil (less cardiovascular side effects expected) and being non-toxic (LD 50 > 2000 mg/kg) are potential agents to overcome MDR problem in clinic.
  • the most preferred thieno[2,3-3 ⁇ 4]pyridines (I) are those listed in the Table 1.
  • OSI- 10248 3-Amino-4,6-bis-(3,4,5-trimethoxyphenyl)-2-(4-methoxybenzoyl)thieno[2,3-3 ⁇ 4]- pyridine-5-carboxylic acid ethyl ester
  • MDR modulating activity of the preferred thieno[2,3-3 ⁇ 4]pyridines of formula (I) are summarized in the Table 3. Table 3. MDR modulating activity of the preferred thieno[2,3-3 ⁇ 4]pyridines of formula (I).
  • thieno[2,3-3 ⁇ 4]pyridines 2-40 (general formula (1-1)) have been prepared starting from original 6-thioxo-l,6-dihydropyridines (yield, melting points and 1H NMR data are combined in tables 4 and 5) or from 6-thioxo-l,6-dihydropyridines prepared according to literature data.
  • the yields, melting points and 1H NMR data of thieno[2,3- 3 ⁇ 4]pyridines (general formula (1-1)) are combined in tables 4 and 5.
  • Table 4 Yields (general procedure) and melting points of thieno[2,3-£]pyridines (I-l).
  • 6-amino-2-thioxo-4-(3,4,5-trimethoxyphenyl)-l,2-dihydropyridine-3,5- dicarbonitrile (63) (0.34 g, 1 mmol) in 10 ml of ethanol 3M sodium hydro xyde water solution (0.8 ml, 2.4 mmol) was added and stirred at room temperature for 10 min.
  • 2- bromo-4'-methoxyacetophenone (0.24 g, 1 mmol) was added and reaction mixture was shortly re fluxed and stirred at room temperature for 30 min.
  • the potency of P-glycoprotein-mediated MDR modulator in vitro was evaluated in the drug sensitive human sarcoma MES-SA cells and doxorubicin (DOX) resistant cells by accumulation of fluorescent substrate - rhodamine 123. Effects on MRPl-mediated drug efflux were observed in the DOX resistant human lung carcinoma H69AR cells using calcein AM assay. BCRPl -mediated drug efflux was also evaluated using fluorescent substrate Hoechst 33342 in the mitoxantrone resistant human sarcoma MESSA/MX2 cells. The half maximal effective concentrations (EC 50 ) were calculated from dose response curve as the most effective method to compare MDR-modulating activities of compounds. MDR modulating activity, intracellular Ca 2+ values and LD 50 values of tested compounds of formula (I) are given in table 3.
  • the MDR modulators were incubated with the cells for 15 min.
  • Hoechst 33342 (5 ⁇ g/ml) was added and the cells were incubated for 90 min, 37 °C, 5% C0 2 .
  • the cells were washed twice with phosphate buffered saline (PBS) and fluorescence values were measured with excitation at 360 nm and emission at 450 nm (Gail M.Seigel and Lorrie M. Campbell, 2004). Imatinib was used as a positive control.
  • the EC50 values were calculated using the program Graph Pad Prism® 4.0
  • calcium channel blockers of all subclasses phenylalkylamine, dihydropyridine and benzothiazepine type
  • calcium antagonists inhibit the P-gp - mediated drug efflux.
  • Calcium antagonists are overcoming P-gp - mediated MDR by mechanisms distinct from their inhibitory effect on voltage-dependent calcium channels. These mechanisms include not only direct interactions with the P-gp protein but also interactions with several other proteins that may indirectly alter P-gp transport activity.
  • Calcium antagonists not only can be inhibitors of P-gp but at the same time some may inhibit P-gp expression via P-gp mRNA down-regulation.
  • the clinical application of calcium antagonists is limited by their severe cardiovascular side effects associated with the high concentration required for reversal of MDR. Hence, cardiotoxicity is a major complication of anticancer drugs including anthracyclines and 5-fluorouracils.
  • the effective MDR modulators with the less than ten times lower Ca 2+ antagonist effect than verapamil, the known P-gp inhibitor, allow to decrease presumable cardiovascular side effects.
  • A7R5 rat aorta smooth muscle cells were grown at 37 °C in a humidified atmosphere with 5% C0 2 /95% air in DMEM medium containing 2 mM glutamine and supplemented with 10% FBS. The cells were seeded into 96 well plate at 10,000 cells/well and incubated for 72 h. The cells were loaded with Fura-4NW for 45 min. The Fura-4NW loaded cells were pre- incubated in the dark for 15 minutes with tested compounds at concentrations from 0.8 to 100 ⁇ .
  • A7R5 cells were pre-treated with 1.5 mM CaCl 2 for 5 minutes and KC1 (50 mM) was added to A7R5 cells to induce [Ca 2+ ]i increase.
  • Amlodipine the well-known calcium channel inhibitor was used as the positive control. Changes in [Ca 2+ ]i were measured from the fluorescence emitted at 516 nm due to alternate excitation at 494 nm using the fluorescence spectrophotometer (Thermo Ascient, Finland). The IC 50 values were calculated using the program Graph Pad Prism® 4.0
  • a low therapeutic index of chemotherapy agents is due to affecting not only cancer formation but also normal cells.
  • Compounds (I) were tested on NIH 3T3 (normal mouse fibroblasts, "ATCC") cell line according the basal toxicity test (INVITOX Protocol No 64, 1992) and non-toxic compounds were selected.
  • LD 50 value is the amount of the drug that is taken to kill 50% of the test animals
  • the IC 50 values were calculated using the program Graph Pad Prism® 4.0
  • NIH3T3 normal mouse fibroblasts
  • HT-1080 human fibrosarcoma
  • MG-22A mouse hepatoma
  • MES-SA human uterine sarcoma
  • MES-SA/Dx5 Doxorubicin resistant, 300 ng/ml
  • H69 human lung carcinoma
  • H69/AR Doxorubicin resistant
  • A7R5 rat aorta smooth muscle
  • MDR appearance is the process of activation of a number of genes and as a result of several proteins overexpression (48 human ABC transporters have been described, more probable MDR associated proteins are P-pg, MRPl and BCRP).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des thiéno[2,3-b]pyridines de formule générale (I), dans laquelle R1 représente Me, C6H5, 3,4,5-(OMe)3C6H2, NH2; R2 représente H, CN, COMe, COO-alkyle en C1 à 4, COOC2H4OMe, COOC2H4 OPr(n); R3 représente C6H4R6, 3,4-OCH2O-C6H3; 2-furanyle; R6 représente 4-Cl, 4-NO2, 4-N(alkyle en C1 à 4)2, 3-(alkyloxy en C1 à 4), 4-(alkyloxy en C1 à 4), 3,4-(alkyloxy en C1 à 4)2, 3,4,5-(alkyloxy en C1 à 4)3; R4 représente NH2, NHCOMe; R5 représente CN, COMe, COC6H4 R7; CO-(2-naphtyle); R7 représente H, 4-F, 4-Cl, 3-OMe, 4-OMe, 2,4-(OMe)2, 3,4,5-(OMe)3 utilisées comme modulateurs de la résistance multiple aux médicaments destinés à augmenter l'efficacité de la chimiothérapie dans le traitement du cancer.
EP13750135.9A 2013-06-11 2013-06-11 Thiéno[2,3-b]pyridines utilisées comme modulateurs de la résistance multiple aux médicaments Active EP3008073B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/054767 WO2014199195A1 (fr) 2013-06-11 2013-06-11 Thiéno[2,3-b]pyridines utilisées comme modulateurs de la résistance multiple aux médicaments

Publications (2)

Publication Number Publication Date
EP3008073A1 true EP3008073A1 (fr) 2016-04-20
EP3008073B1 EP3008073B1 (fr) 2020-01-01

Family

ID=48986167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13750135.9A Active EP3008073B1 (fr) 2013-06-11 2013-06-11 Thiéno[2,3-b]pyridines utilisées comme modulateurs de la résistance multiple aux médicaments

Country Status (5)

Country Link
US (1) US9908893B2 (fr)
EP (1) EP3008073B1 (fr)
CA (1) CA2910514C (fr)
EA (1) EA201690089A1 (fr)
WO (1) WO2014199195A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043720B (zh) * 2022-07-04 2023-11-21 新疆医科大学 一种新型α-甲基查耳酮类化合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
CN1968954A (zh) 2004-04-12 2007-05-23 三共株式会社 噻吩并吡啶衍生物
WO2006019832A1 (fr) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0517438A (pt) 2004-10-25 2008-10-07 Lilly Co Eli composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
JP5173429B2 (ja) 2004-12-09 2013-04-03 ゼンション・リミテッド 化合物
WO2006063732A1 (fr) 2004-12-17 2006-06-22 F.Hoffmann-La Roche Ag Derives de la thieno-pyridine renforçateurs allosteriques du gaba-b
WO2006074919A2 (fr) 2005-01-12 2006-07-20 Curacyte Discovery Gmbh Amides d'acide 3-amino-6-aryl-thieno[2,3-b]pyridine-2-carboxylique, preparations pharmaceutiques contenant ces composes et utilisation desdits composes comme inhibiteurs de la liberation de tnf$g(a)
HUP0501170A2 (en) 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
HUP0501168A3 (en) 2005-12-20 2007-10-29 Richter Gedeon Nyrt 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US8710097B2 (en) * 2006-05-19 2014-04-29 The Hong Kong Polytechnic University Flavonoid dimers and methods of making and using such
EP2029608A1 (fr) 2006-06-06 2009-03-04 Boehringer Ingelheim International GmbH COMPOSÉS AMIDE DE L'ACIDE 3-AMINO-THIÉNO[2,3-b]PYRIDINE-2-CARBOXYLIQUE SUBSTITUÉS, PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
WO2009062288A1 (fr) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2009093008A1 (fr) 2008-01-21 2009-07-30 Ucb Pharma S.A. Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2308883A1 (fr) * 2009-10-05 2011-04-13 Centre National De La Recherche Scientifique Nouveaux dérivés de thiéno[2,3-b]pyridine et 5,6,7,8 tétrahydrothiéno[2,3 b]quinoline utiles en particulier pour le traitement du paludisme
EP2512242B8 (fr) 2009-12-18 2015-12-09 GlaxoSmithKline Intellectual Property Limited Nouveaux composés
US8759371B2 (en) 2010-07-01 2014-06-24 Amgen Inc. Heterocyclic compounds and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014199195A1 *

Also Published As

Publication number Publication date
US20160137664A1 (en) 2016-05-19
CA2910514A1 (fr) 2014-12-18
CA2910514C (fr) 2018-05-15
US9908893B2 (en) 2018-03-06
EP3008073B1 (fr) 2020-01-01
EA201690089A1 (ru) 2017-04-28
WO2014199195A1 (fr) 2014-12-18

Similar Documents

Publication Publication Date Title
CA2730319C (fr) Composes tricycliques ayant une activite antimitotique et/ou antitumorale et leurs procedes d'utilisation
CA2698018C (fr) Composes tricycliques ayant une activite cytostatique et/ou cytotoxique et leurs procedes d'utilisation
AU2014294109B2 (en) Quinoline derivative
JP6559123B2 (ja) Ｋｒａｓｇ１２ｃの阻害剤
JP4890723B2 (ja) ＴＮＦαインヒビターとして有用なクマリン誘導体
JP2015520186A (ja) 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物
JP2016517412A (ja) Ｆａｓｎを阻害するための新規化合物および組成物
JP2008520749A (ja) 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
KR20030005336A (ko) 피페라진디온 화합물
KR20170081708A (ko) 헤테로환형 유도체 및 이의 용도
KR20150119926A (ko) 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀
KR20150005698A (ko) 키나제 저해제로서 유용한 치환된 아미노퀴나졸린
JP2008521854A5 (fr)
JP2006517949A (ja) キナーゼ阻害剤としての四環系ピラゾール誘導体、前記誘導体の製造方法、および前記誘導体を含む医薬組成物
JP2005526764A (ja) ピリミジン化合物
WO2014199195A1 (fr) Thiéno[2,3-b]pyridines utilisées comme modulateurs de la résistance multiple aux médicaments
ES2941263T3 (es) Nuevos análogos como moduladores del receptor de andrógenos y del receptor de glucocorticoides
JP2004532241A5 (fr)
WO2014071824A1 (fr) Composé hétérocyclique 4-quinazolinamine et utilisation de celui-ci
JP6255509B2 (ja) 縮合アクリジン誘導体及びその医薬組成物、製造方法及び応用
TW200418853A (en) Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
EP4065572A1 (fr) Dérivés de benzylamide utilisés en tant qu'inhibiteurs du récepteur i/alk5 du facteur de croissance transformant bêta
Darwish et al. A decade's overview of 2‐aminothiophenes and their fused analogs as promising anticancer agents
JP2021530472A (ja) 癌の予防または治療に使用するための化合物
ES2776177T3 (es) Derivados nuevos de indol para el tratamiento del cáncer, infecciones virales y enfermedades pulmonares

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170207

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 495/04 20060101AFI20190522BHEP

Ipc: A61K 31/4365 20060101ALI20190522BHEP

Ipc: A61P 35/00 20060101ALI20190522BHEP

INTG Intention to grant announced

Effective date: 20190611

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190725

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1219663

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013064613

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200101

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200527

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200401

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200501

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200401

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200402

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013064613

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1219663

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200101

26N No opposition filed

Effective date: 20201002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200611

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200611

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200611

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20210623

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200101

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013064613

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230103